2022 U.S. Women’s Health Testing Market Report: $106 Billion Market by 2030

company logo

company logo

US Women’s Health Testing Market

US Women's Health Testing Market

US Women’s Health Testing Market

Dublin, February 17, 2023 (GLOBE NEWSWIRE) — “US Women’s Health Testing Market – Analysis by Region: Focus on US Women’s Health Testing Market – Analysis and Forecast, 2022-2030” report added of ResearchAndMarkets.com Recruitment.

The US women’s health testing market was valued at $72.8 billion in 2021 and is expected to reach $106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030. You can

The market is driven by factors such as rising prevalence of infectious diseases and cancer among women, increasing awareness of women’s health-related testing, rising average maternal age leading to increased risk of fetal chromosomal aneuploidy, and rapid reproductive health. towed by Issues leading to increased demand for clinical testing of women.

The US women’s health testing market is in a developing stage. Advancements in diagnostic technology, including the application of genetic testing in women’s health, and mergers and acquisitions of numerous companies to gain better market share are some of the major opportunities in the US women’s health testing market.

How can this report bring value to your organization?

The different segments of the report help readers understand the different types of tests/services for women’s health available in the market.

Additionally, this study provides an in-depth understanding of tests/services that fall into various segments such as hereditary cancer, carrier screening, prenatal screening, diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology. provide the reader with

Growth/Marketing Strategies: The U.S. Women’s Health Laboratory Testing market is driven by key players operating in the market including product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, regulatory and legal approvals. We are witnessing great progress.

A preferred strategy for companies is regulatory and legal action to strengthen the position of their products in the US market. For example, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved myChoice CDx as a companion diagnostic for her Zejula treatment of late-stage ovarian cancer.

Main indicators

report attribute


number of pages


Forecast period


Estimated market value in 2022 (USD)

$76.2 billion

Projected market value to 2030 (USD)

$106.8 billion

compound annual growth rate


Target area


Recent Developments in the U.S. Women’s Health Testing Market

  • In November 2022, Roche Holdings launched Cobas 5800, a new molecular diagnostic system that expands access to PCR testing in the United States. and sexually transmitted diseases.

  • In February 2022, Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities.

  • In January 2022, Yourgene announced that it has entered into a strategic partnership agreement with EKF Diagnostics Holdings plc, a point-of-care business with accredited laboratory testing capabilities in the United States

  • In November 2022, Myriad Genetics announced the acquisition of Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.

  • In August 2022, Natera, Inc. announced that it has actively submitted a pre-application for the Panorama Non-Invasive Prenatal Test (NIPT) to the FDA as part of the Q-Sub process.

market segmentation

  • The US women’s health testing market (hereditary cancer) is expected to be dominated by the cervical cancer segment.

  • The US women’s health testing market (prenatal screening and diagnostic tests) is dominated by the non-invasive prenatal testing segment.

  • The US women’s health testing market (reproductive health and infectious diseases) is dominated by the HIV testing segment.

  • The US women’s health testing market (by region) is dominated by the Southern region segment.

Featured company

Main topics:

1 market
1.1 US Market Outlook
1.1.1 Product definition
1.1.2 Inclusion and exclusion criteria
1.2 Business dynamics
1.2.1 Impact analysis
1.2.2 Business drivers Increasing Prevalence of Infectious Diseases and Cancer in Women Increases Demand for Laboratory Tests Growing awareness of women’s health-related examinations Increasing mean maternal age associated with increased risk of fetal chromosomal aneuploidy Rising Reproductive Health Issues Increase Demand for Female Clinical Testing
1.2.3 Business restrictions Strict regulatory guidelines related to laboratory testing hindering market growth in the US Disparities in Perceptions of Pregnancy and Infertility Issues in Different Regions of the United States
1.2.4 Business Opportunities Advances in diagnostic technology, including the application of genetic testing in women’s health Healthcare disparities in rural areas of the United States Gaps in health care for women of childbearing age with psychological distress Significant number of mergers and acquisitions by companies to achieve better market share

2 US Women’s Health Testing Market (By Hereditary Cancers)
2.1 Overview
2.2 Breast cancer
2.2.1 Epidemiology
2.2.2 Test Market
2.2.3 Testing Market (by Region)
2.3 Cervical cancer
2.4 Ovarian cancer

3 US Women’s Health Laboratory Testing Market (By Carrier Screening)
3.1 Overview
3.1.1 Test market
3.1.2 Testing Market (by Region)

4 US Women’s Health Testing Market (By Prenatal Screening and Diagnostic Testing)
4.1 Overview
4.2 Non-Invasive Prenatal Testing (NIPT)
4.3 Maternal Serum Screening (MSS)
4.4 Prenatal diagnostic tests

5 US Women’s Health Testing Market (by Reproductive Health and Infectious Diseases)
5.1 Overview
5.2 Pregnancy and ovulation tests
5.3 HPV testing
5.4 PAP smear test
5.5 HIV testing
5.6 CT/NG test
5.7 Preimplantation genetic testing (PGT)
5.8 Sexually transmitted diseases (syphilis, gonorrhea, chlamydia)
5.9 Herpes Simplex Virus (HSV)
5.10 Hepatitis
5.11 Vaginal infections

6 US Women’s Health Testing Market (by Obstetrics and Gynecology)
6.1 Overview
6.1.1 Testing Market (By Region)

Learn more about this report here https://www.researchandmarkets.com/r/wyrvwd-s-women-health?w=12

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. It provides up-to-date data on international and regional markets, key industries, top companies, new products and latest trends.


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to content